Exact Sciences (NASDAQ:EXAS) Given New $65.00 Price Target at The Goldman Sachs Group

Exact Sciences (NASDAQ:EXAS) had its price target dropped by research analysts at The Goldman Sachs Group from $75.00 to $65.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. The Goldman Sachs Group’s target price would suggest a potential upside of 25.10% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Raymond James reissued a “market perform” rating on shares of Exact Sciences in a research note on Thursday, September 26th. Piper Sandler increased their target price on Exact Sciences from $75.00 to $85.00 and gave the company an “overweight” rating in a research note on Thursday, September 12th. Benchmark dropped their target price on shares of Exact Sciences from $67.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday. Robert W. Baird lowered their target price on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Craig Hallum cut their target price on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $77.12.

Exact Sciences Price Performance

NASDAQ:EXAS traded down $19.55 during mid-day trading on Wednesday, reaching $51.96. 9,093,962 shares of the company were exchanged, compared to its average volume of 2,558,984. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. Exact Sciences has a 12 month low of $40.62 and a 12 month high of $79.62. The stock has a market cap of $9.60 billion, a PE ratio of -54.04 and a beta of 1.27. The company has a fifty day moving average of $67.27 and a 200 day moving average of $56.67.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business had revenue of $708.66 million for the quarter, compared to the consensus estimate of $716.80 million. The firm’s quarterly revenue was up 12.8% on a year-over-year basis. On average, research analysts anticipate that Exact Sciences will post -0.87 EPS for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the company’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at $893,060. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 1.36% of the company’s stock.

Institutional Trading of Exact Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Huntington National Bank grew its stake in Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after purchasing an additional 352 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in Exact Sciences in the second quarter valued at approximately $29,000. Capital Performance Advisors LLP bought a new position in shares of Exact Sciences in the third quarter valued at approximately $35,000. Vestor Capital LLC bought a new position in shares of Exact Sciences in the third quarter valued at approximately $46,000. Finally, V Square Quantitative Management LLC bought a new position in shares of Exact Sciences in the third quarter valued at approximately $47,000. 88.82% of the stock is currently owned by institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.